A 50-year-old man is more likely to die from complications of a bone fracture than prostate cancer. Yet only 2% of older men ...

DUBAI, DUBAI, UNITED ARAB EMIRATES, February 24, 2026 /EINPresswire.com/ -- ANY.RUN researchers have identified ...

New research from Microsoft has revealed that legitimate businesses are gaming artificial intelligence (AI) chatbots via the "Summarize with AI" button that's being increasingly placed on websites in ...

That helpful “Summarize with AI” button? It might be secretly manipulating what your AI recommends. Microsoft security researchers have discovered a growing trend of AI memory poisoning attacks used ...

Thirty-eight years ago, I was initiated into the oldest and one of the largest Black fraternities in the world: Alpha Phi Alpha Fraternity, Inc. It was one of the happiest days of my life. In ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

A research team at the University of Würzburg has, for the first time, uncovered how E. coli bacteria sneak into the prostate. The study opens the door to potential new treatments for bacterial ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Daniel Kelly does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...